ArticleJournal of cancer research and clinical oncology2024

Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib.

Zhiyuan Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.